Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Urban Outfitters announced partnership with FABSCRAP to address textile waste » 09:11
04/19/21
04/19
09:11
04/19/21
09:11
URBN

Urban Outfitters

$37.26 /

+0.22 (+0.59%)

Urban Outfitters…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
URBN Urban Outfitters
$37.26 /

+0.22 (+0.59%)

URBN Urban Outfitters
$37.26 /

+0.22 (+0.59%)

06:58 Today Deutsche Bank
Urban Outfitters price target raised to $39 from $32 at Deutsche Bank
04/13/21 B. Riley
Urban Outfitters price target raised to $36 from $30 at B. Riley
04/13/21 Morgan Stanley
Urban Outfitters price target raised to $44 from $37 at Morgan Stanley
04/13/21 Barclays
Urban Outfitters price target raised to $47 from $38 at Barclays
URBN Urban Outfitters
$37.26 /

+0.22 (+0.59%)

URBN Urban Outfitters
$37.26 /

+0.22 (+0.59%)

URBN Urban Outfitters
$37.26 /

+0.22 (+0.59%)

Hot Stocks
iCAD presented new data for ProFound AI breast cancer detection » 08:17
04/19/21
04/19
08:17
04/19/21
08:17
ICAD

iCAD

$17.79 /

-0.73 (-3.94%)

iCAD announced that new…

iCAD announced that new research supporting the clinical value of ProFound AI for Digital Breast Tomosynthesis was presented at the Society of Breast Imaging Symposium, April 9-11, and at the National Consortium of Breast Centers Annual Interdisciplinary Breast Center Conference, April 16-19. Emily Conant, MD, Professor and Division Chief of Breast Imaging at the University of Pennsylvania Medical Center, presented findings from a retrospective analysis involving ProFound AI for DBT in a presentation titled "Feasibility of automated identification of low-likelihood of cancer cases in digital breast tomosynthesis screening," at the SBI Symposium. At the NCoBC Interdisciplinary Breast Center Conference, Mark Traill, MD, University of Michigan Health, presented findings from a study titled "Correlation between BI-RADS Assessment Categories and Artificial Intelligence Case Scores," which was a winner in the "Breast Disease Diagnosis and Management" category. According to study findings presented by Conant at the SBI Symposium, ProFound AI for DBT accurately identified 33.4% of normal screening DBT exams with no cancers being missed, based solely on the ProFound AI Case Score. When researchers also factored in breast density and age, ProFound AI identified 58.6% of normal cases with no false negatives. The study was conducted to evaluate the thresholds at which the ProFound AI system could be used for triaging DBT exams to reach a minimum rate of false negatives per 1,000 screened in an enriched dataset of 506 biopsy-proven cancer cases and 1,293 non-cancer cases with 320 days of negative follow-up. A consecutive series of cases were collected from 18 sites in the United States and three sites in France. In addition, new data presented by Mark Traill at the NCoBC Interdisciplinary Breast Center Conference highlights the comparison of ProFound AI Case Scores to BI-RADS assessment categories determined by a single radiologist without using AI in a retrospective analysis. Researchers used ProFound AI on 890 consecutive DBT studies and 50 consecutive cases with biopsy-proven breast cancer detected with DBT. Results showed a strong positive correlation between a ProFound AI Case Score of less than 60 percent and patients assessed as likely to be normal, while most of the biopsy-proven cancers had a Case Score of greater than 60%.

ShowHide Related Items >><<
ICAD iCAD
$17.79 /

-0.73 (-3.94%)

ICAD iCAD
$17.79 /

-0.73 (-3.94%)

03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
ICAD iCAD
$17.79 /

-0.73 (-3.94%)

  • 03
    Mar
ICAD iCAD
$17.79 /

-0.73 (-3.94%)

Recommendations
Urban Outfitters price target raised to $39 from $32 at Deutsche Bank » 06:58
04/19/21
04/19
06:58
04/19/21
06:58
URBN

Urban Outfitters

/

+

Deutsche Bank analyst…

Deutsche Bank analyst Gabriella Carbone raised the firm's price target on Urban Outfitters to $39 from $32 and keeps a Hold rating on the shares following the company's "positive" Q1 update.

ShowHide Related Items >><<
URBN Urban Outfitters
/

+

URBN Urban Outfitters
/

+

04/13/21 B. Riley
Urban Outfitters price target raised to $36 from $30 at B. Riley
04/13/21 Morgan Stanley
Urban Outfitters price target raised to $44 from $37 at Morgan Stanley
04/13/21 Barclays
Urban Outfitters price target raised to $47 from $38 at Barclays
04/12/21 Oppenheimer
Urban Outfitters sales growth has improved meaningfully, says Oppenheimer
URBN Urban Outfitters
/

+

URBN Urban Outfitters
/

+

URBN Urban Outfitters
/

+

Saturday
On The Fly
Opening Day: Coinbase soars in market debut » 09:03
04/17/21
04/17
09:03
04/17/21
09:03
RXRX

Recursion Pharmaceuticals

$31.06 /

+0.81 (+2.68%)

, BMEA

Biomea Fusion

$18.48 /

-1.92 (-9.41%)

, AKYA

Akoya Biosciences

$26.92 /

+0.18 (+0.67%)

, APP

AppLovin

$61.01 /

-3.795 (-5.86%)

, AGL

Agilon Health

$30.45 /

-0.43 (-1.39%)

, KRT

Karat Packaging

$18.38 /

-0.52 (-2.75%)

, TSP

TuSimple

$39.99 /

+0.53 (+1.34%)

, EBET

Esports Technologies

$25.35 /

-10.69 (-29.66%)

, COIN

Coinbase

$341.27 /

+15.78 (+4.85%)

, ALKT

Alkami

$42.13 /

-0.13 (-0.31%)

, SQSP

Squarespace

/

+

, SVFD

Save Foods

/

+

, RGCB

Regencell Bioscience

/

+

, SWIM

Latham Group

/

+

, EDR

Endeavor

$41.49 /

+ (+0.00%)

, UBER

Uber

$60.34 /

-0.405 (-0.67%)

, LYFT

Lyft

$63.36 /

-1.07 (-1.66%)

Shares of Coinbase jumped…

ShowHide Related Items >><<
UBER Uber
$60.34 /

-0.405 (-0.67%)

LYFT Lyft
$63.36 /

-1.07 (-1.66%)

COIN Coinbase
$341.27 /

+15.78 (+4.85%)

RXRX Recursion Pharmaceuticals
$31.06 /

+0.81 (+2.68%)

BMEA Biomea Fusion
$18.48 /

-1.92 (-9.41%)

AKYA Akoya Biosciences
$26.92 /

+0.18 (+0.67%)

APP AppLovin
$61.01 /

-3.795 (-5.86%)

AGL Agilon Health
$30.45 /

-0.43 (-1.39%)

KRT Karat Packaging
$18.38 /

-0.52 (-2.75%)

TSP TuSimple
$39.99 /

+0.53 (+1.34%)

EBET Esports Technologies
$25.35 /

-10.69 (-29.66%)

COIN Coinbase
$341.27 /

+15.78 (+4.85%)

04/15/21 Loop Capital
Loop Capital starts Coinbase at Buy, sees 'lots of runway before takeoff'
04/15/21 Loop Capital
Coinbase initiated with a Buy at Loop Capital
04/15/21
Fly Intel: Top five analyst initiations
04/15/21 DA Davidson
Coinbase price target raised to $650 from $440 at DA Davidson
ALKT Alkami
$42.13 /

-0.13 (-0.31%)

SQSP Squarespace
/

+

SVFD Save Foods
/

+

RGCB Regencell Bioscience
/

+

SWIM Latham Group
/

+

EDR Endeavor
$41.49 /

+ (+0.00%)

UBER Uber
$60.34 /

-0.405 (-0.67%)

04/12/21 Truist
Uber's March update 'bodes well' for Q1 and FY21 outlook, says Truist
04/05/21 Evercore ISI
Uber assumed with an Outperform at Evercore ISI
04/01/21
Fly Intel: Top five analyst initiations
04/01/21 Jefferies
Uber initiated with a Buy at Jefferies
LYFT Lyft
$63.36 /

-1.07 (-1.66%)

04/05/21 Evercore ISI
Lyft assumed with an Outperform at Evercore ISI
03/31/21 Wolfe Research
Lyft assumed with a Peer Perform at Wolfe Research
03/26/21
Fly Intel: Top five analyst initiations
03/26/21 Vertical Research
Lyft initiated with a Buy at Vertical Research
UBER Uber
$60.34 /

-0.405 (-0.67%)

LYFT Lyft
$63.36 /

-1.07 (-1.66%)

COIN Coinbase
$341.27 /

+15.78 (+4.85%)

  • 23
    Apr
  • 14
    Apr
  • 15
    Apr
  • 16
    Apr
  • 16
    Apr
  • 16
    Apr
  • 15
    Apr
  • 15
    Apr
  • 15
    Apr
  • 14
    Apr
  • 15
    Apr
  • 08
    Jan
UBER Uber
$60.34 /

-0.405 (-0.67%)

TSP TuSimple
$39.99 /

+0.53 (+1.34%)

LYFT Lyft
$63.36 /

-1.07 (-1.66%)

COIN Coinbase
$341.27 /

+15.78 (+4.85%)

UBER Uber
$60.34 /

-0.405 (-0.67%)

SQSP Squarespace
/

+

LYFT Lyft
$63.36 /

-1.07 (-1.66%)

EBET Esports Technologies
$25.35 /

-10.69 (-29.66%)

COIN Coinbase
$341.27 /

+15.78 (+4.85%)

AGL Agilon Health
$30.45 /

-0.43 (-1.39%)

UBER Uber
$60.34 /

-0.405 (-0.67%)

LYFT Lyft
$63.36 /

-1.07 (-1.66%)

Friday
Periodicals
Airbnb CEO tells CNBC company will need millions more hosts to meet demand » 12:22
04/16/21
04/16
12:22
04/16/21
12:22
ABNB

Airbnb

$176.85 /

+1.63 (+0.93%)

Airbnb CEO Brian Chesky…

Airbnb CEO Brian Chesky told CNBC that the company will need to add millions of new hosts to accommodate guests as travel picks up as the COVID-19 pandemic begins to subside. "To meet the demand over the coming years, we're going to need millions more hosts," Chesky said on CNBC's "TechCheck." "I think that we probably will have a high cost problem where there will probably be more guests coming to Airbnb than we'll have hosts for, because ... we think there's going to be a travel rebound coming that's unlike anything we've ever seen," the CEO added. "We are working our hardest to get more hosts on the platform." Reference Link

ShowHide Related Items >><<
ABNB Airbnb
$176.85 /

+1.63 (+0.93%)

ABNB Airbnb
$176.85 /

+1.63 (+0.93%)

04/05/21 Evercore ISI
Airbnb initiated with an Outperform at Evercore ISI
03/31/21 Wolfe Research
Airbnb assumed with a Peer Perform at Wolfe Research
03/10/21 Citi
Airbnb resumed with a Neutral at Citi
03/03/21 Truist
Airbnb price target raised to $180 from $154 at Truist
ABNB Airbnb
$176.85 /

+1.63 (+0.93%)

  • 10
    Dec
ABNB Airbnb
$176.85 /

+1.63 (+0.93%)

ABNB Airbnb
$176.85 /

+1.63 (+0.93%)

ABNB Airbnb
$176.85 /

+1.63 (+0.93%)

Options
Nordstrom put volume heavy and directionally bearish » 11:35
04/16/21
04/16
11:35
04/16/21
11:35
JWN

Nordstrom

$35.33 /

-0.58 (-1.62%)

Bearish flow noted in…

Bearish flow noted in Nordstrom with 1,260 puts trading, or 1.3x expected. Most active are May-21 32.5 puts and Apr-21 30 puts, with total volume in those strikes near 460 contracts. The Put/Call Ratio is 2.36, while ATM IV is up over 5 points on the day. Earnings are expected on May 27th.

ShowHide Related Items >><<
JWN Nordstrom
$35.33 /

-0.58 (-1.62%)

JWN Nordstrom
$35.33 /

-0.58 (-1.62%)

03/12/21
Fly Intel: Top five analyst initiations
03/12/21 Jefferies
Jefferies picks Macy's, Kohl's and Nordstrom as department store 'survivors'
03/12/21 Jefferies
Nordstrom initiated with a Buy at Jefferies
02/16/21 JPMorgan
Nordstrom price target raised to $40 from $34 at JPMorgan
JWN Nordstrom
$35.33 /

-0.58 (-1.62%)

JWN Nordstrom
$35.33 /

-0.58 (-1.62%)

JWN Nordstrom
$35.33 /

-0.58 (-1.62%)

JWN Nordstrom
$35.33 /

-0.58 (-1.62%)

Thursday
Options
Nordstrom put volume heavy and directionally bearish » 13:15
04/15/21
04/15
13:15
04/15/21
13:15
JWN

Nordstrom

$35.57 /

-1.58 (-4.25%)

Bearish flow noted in…

Bearish flow noted in Nordstrom with 1,842 puts trading, or 1.2x expected. Most active are 5/14 weekly 33 puts and Apr-21 25 puts, with total volume in those strikes near 810 contracts. The Put/Call Ratio is 2.28, while ATM IV is up over 2 points on the day. Earnings are expected on May 27th.

ShowHide Related Items >><<
JWN Nordstrom
$35.57 /

-1.58 (-4.25%)

JWN Nordstrom
$35.57 /

-1.58 (-4.25%)

03/12/21
Fly Intel: Top five analyst initiations
03/12/21 Jefferies
Jefferies picks Macy's, Kohl's and Nordstrom as department store 'survivors'
03/12/21 Jefferies
Nordstrom initiated with a Buy at Jefferies
02/16/21 JPMorgan
Nordstrom price target raised to $40 from $34 at JPMorgan
JWN Nordstrom
$35.57 /

-1.58 (-4.25%)

JWN Nordstrom
$35.57 /

-1.58 (-4.25%)

JWN Nordstrom
$35.57 /

-1.58 (-4.25%)

JWN Nordstrom
$35.57 /

-1.58 (-4.25%)

Recommendations
Ross Stores price target raised to $145 from $130 at Loop Capital » 09:23
04/15/21
04/15
09:23
04/15/21
09:23
ROST

Ross Stores

$126.90 /

+0.43 (+0.34%)

Loop Capital analyst…

Loop Capital analyst Laura Champine raised the firm's price target on Ross Stores to $145 from $130 and keeps a Buy rating on the shares as part of a broader research note into Diversified Retail names. The company should pick up market share at a faster pace given the "wounds inflicted on weaker department and specialty stores in FY20", the analyst tells investors in a research note, adding that its stores are "well-stocked" with no inventory overhang.

ShowHide Related Items >><<
ROST Ross Stores
$126.90 /

+0.43 (+0.34%)

ROST Ross Stores
$126.90 /

+0.43 (+0.34%)

03/18/21 Deutsche Bank
Ross Stores named 'Short-Term Catalyst Buy' at Deutsche Bank
03/05/21 Evercore ISI
Burlington Stores price target raised to $290 from $225 at Evercore ISI
03/05/21 UBS
Ross Stores price target lowered to $120 from $125 at UBS
01/21/21 Deutsche Bank
Ross Stores price target raised to $129 from $123 at Deutsche Bank
ROST Ross Stores
$126.90 /

+0.43 (+0.34%)

ROST Ross Stores
$126.90 /

+0.43 (+0.34%)

ROST Ross Stores
$126.90 /

+0.43 (+0.34%)

ROST Ross Stores
$126.90 /

+0.43 (+0.34%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
04/15/21
04/15
04:55
04/15/21
04:55
MDGEF

MediGene

$4.80 /

+ (+0.00%)

, GLSI

Greenwich LifeSciences

$35.13 /

-0.92 (-2.55%)

, JNCE

Jounce Therapeutics

$9.74 /

+0.485 (+5.24%)

, ATNM

Actinium Pharmaceuticals

$7.80 /

+0.23 (+3.04%)

, BDTX

Black Diamond Therapeutics

$24.70 /

-0.7199 (-2.83%)

, CRSP

Crispr Therapeutics

$123.29 /

+2.34 (+1.93%)

, HARP

Harpoon Therapeutics

$20.61 /

+0.73 (+3.67%)

, ITOS

iTeos Therapeutics

$24.03 /

-1.24 (-4.91%)

, REPL

Replimune Group

$30.50 /

+0.32 (+1.06%)

, RVMD

Revolution Medicines

$39.79 /

+2.18 (+5.80%)

, ZNTL

Zentalis

$47.04 /

+1.43 (+3.14%)

, IMCR

Immunocore

$39.50 /

+6.8 (+20.80%)

, PMVP

PMV Pharmaceuticals

$32.90 /

+0.06 (+0.18%)

, ARVN

Arvinas

$62.89 /

+1.62 (+2.64%)

, IOVA

Iovance Biotherapeutics

$30.00 /

-0.17 (-0.56%)

, ADXS

Advaxis

/

+

, AGEN

Agenus

$2.70 /

-0.015 (-0.55%)

, BPTH

Bio-Path

$6.21 /

-0.41 (-6.19%)

, INCY

Incyte

$82.13 /

+1.5 (+1.86%)

, IMAB

I-MAB

$55.17 /

+5.42 (+10.89%)

, MRSN

Mersana Therapeutics

$17.06 /

+0.89 (+5.50%)

, RUBY

Rubius Therapeutics

$23.77 /

+1.27 (+5.64%)

, PPBT

Purple Biotech

$4.04 /

+ (+0.00%)

, SONN

Sonnet BioTherapeutics

$2.11 /

-0.02 (-0.94%)

, STTK

Shattuck Labs

$32.98 /

+0.56 (+1.73%)

, SURF

Surface Oncology

$7.35 /

+0.095 (+1.31%)

, BGNE

BeiGene

$300.84 /

+0.84 (+0.28%)

, CMPI

Checkmate Pharmaceuticals

$7.44 /

+0.3 (+4.20%)

, BNGO

Bionano Genomics

$6.42 /

-0.47 (-6.82%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on April 9-15. Webcast Link

ShowHide Related Items >><<
ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

STTK Shattuck Labs
$32.98 /

+0.56 (+1.73%)

SONN Sonnet BioTherapeutics
$2.11 /

-0.02 (-0.94%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

PPBT Purple Biotech
$4.04 /

+ (+0.00%)

PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

ITOS iTeos Therapeutics
$24.03 /

-1.24 (-4.91%)

IOVA Iovance Biotherapeutics
$30.00 /

-0.17 (-0.56%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

IMAB I-MAB
$55.17 /

+5.42 (+10.89%)

HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

CMPI Checkmate Pharmaceuticals
$7.44 /

+0.3 (+4.20%)

BPTH Bio-Path
$6.21 /

-0.41 (-6.19%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

BGNE BeiGene
$300.84 /

+0.84 (+0.28%)

BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

ATNM Actinium Pharmaceuticals
$7.80 /

+0.23 (+3.04%)

ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

AGEN Agenus
$2.70 /

-0.015 (-0.55%)

ADXS Advaxis
/

+

MDGEF MediGene
$4.80 /

+ (+0.00%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
ATNM Actinium Pharmaceuticals
$7.80 /

+0.23 (+3.04%)

04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
12/29/20 H.C. Wainwright
H.C. Wainwright keeps Buy on Actinium amid 'headline disappointment'
12/29/20 JonesTrading
Actinium selloff today 'clear buying opportunity,' says JonesTrading
11/05/20
Fly Intel: Top five analyst initiations
BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
11/24/20 Berenberg
Black Diamond Therapeutics initiated with a Buy at Berenberg
CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

03/17/21 Guggenheim
Editas Medicine assumed with a Neutral at Guggenheim
03/04/21 JMP Securities
Crispr Therapeutics initiated with an Outperform at JMP Securities
03/01/21 Barclays
Crispr Therapeutics price target raised to $140 from $113 at Barclays
02/17/21 Goldman Sachs
Crispr Therapeutics price target lowered to $189 from $193 at Goldman Sachs
HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

03/11/21 Roth Capital
Harpoon's 2020/2021 should be 'festival of data,' says Roth Capital
01/04/21 Roth Capital
Harpoon having fourth candidate in clinic 'impressive,' says Roth Capital
12/23/20 H.C. Wainwright
Harpoon Therapeutics assumed with a Buy at H.C. Wainwright
12/16/20 Wedbush
Replimune Group, Harpoon Therapeutics removed from Best Ideas List at Wedbush
ITOS iTeos Therapeutics
$24.03 /

-1.24 (-4.91%)

04/12/21 Piper Sandler
iTeos Therapeutics' EOS-448 'competitive' in TIGIT class, says Piper Sandler
04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
04/05/21 Piper Sandler
Piper Sandler continues to recommend iTeos Therapeutics into data
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

02/05/21 H.C. Wainwright
Replimune Group price target raised to $60 from $58 at H.C. Wainwright
11/17/20 BTIG
Replimune Group initiated with a Buy at BTIG
11/10/20 H.C. Wainwright
Replimune Group price target raised to $58 from $54 at H.C. Wainwright
RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

03/03/21 SVB Leerink
Revolution Medicines price target raised to $55 from $46 at SVB Leerink
01/29/21 JPMorgan
Revolution Medicines price target raised to $44 from $33 at JPMorgan
10/26/20 H.C. Wainwright
Revolution Medicines price target raised to $54 from $52 at H.C. Wainwright
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

04/12/21 SVB Leerink
Zentalis price target raised to $60 from $44 at SVB Leerink
03/26/21 H.C. Wainwright
Zentalis price target raised to $65 from $43 at H.C. Wainwright
01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

10/20/20 Evercore ISI
PMV Pharmaceuticals initiated with an Outperform at Evercore ISI
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 BofA
PMV Pharmaceuticals initiated with a Buy at BofA
10/20/20 Cowen
PMV Pharmaceuticals initiated with an Outperform at Cowen
ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

03/31/21 BMO Capital
Arvinas initiated with an Outperform at BMO Capital
03/30/21 Cantor Fitzgerald
Arvinas price target raised to $140 from $121 at Cantor Fitzgerald
03/01/21 Roth Capital
Arvinas reaffirmed 'major catalysts' for 2021, says Roth Capital
01/19/21 Oppenheimer
Arvinas price target raised to $100 from $80 at Oppenheimer
IOVA Iovance Biotherapeutics
$30.00 /

-0.17 (-0.56%)

04/13/21 Cowen
Cowen starts Instil Bio at Outperform on 'second-mover advantage'
03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
ADXS Advaxis
/

+

AGEN Agenus
$2.70 /

-0.015 (-0.55%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
BPTH Bio-Path
$6.21 /

-0.41 (-6.19%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
INCY Incyte
$82.13 /

+1.5 (+1.86%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
IMAB I-MAB
$55.17 /

+5.42 (+10.89%)

03/15/21 Needham
I-MAB initiated with a Buy at Needham
03/03/21 H.C. Wainwright
I-MAB price target raised to $75 from $55 at H.C. Wainwright
02/25/21
Fly Intel: Top five analyst initiations
02/25/21 Piper Sandler
I-MAB initiated with an Overweight at Piper Sandler
MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
09/29/20 JPMorgan
Mersana Therapeutics resumed with a Neutral at JPMorgan
RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

03/15/21 H.C. Wainwright
Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
PPBT Purple Biotech
$4.04 /

+ (+0.00%)

12/31/20 H.C. Wainwright
H.C. Wainwright reiterates Buy, $25 price target on Purple Biotech
SONN Sonnet BioTherapeutics
$2.11 /

-0.02 (-0.94%)

09/04/20 Chardan
Sonnet BioTherapeutics price target raised to $8 from $7 at Chardan
06/05/20 Chardan
Sonnet BioTherapeutics initiated with a Buy at Chardan
STTK Shattuck Labs
$32.98 /

+0.56 (+1.73%)

04/14/21 Berenberg
Shattuck Labs initiated with a Buy at Berenberg
01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
BGNE BeiGene
$300.84 /

+0.84 (+0.28%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
CMPI Checkmate Pharmaceuticals
$7.44 /

+0.3 (+4.20%)

03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
09/01/20 BofA
BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
09/01/20 BofA
Checkmate Pharmaceuticals initiated with a Neutral at BofA
BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

STTK Shattuck Labs
$32.98 /

+0.56 (+1.73%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

ITOS iTeos Therapeutics
$24.03 /

-1.24 (-4.91%)

IOVA Iovance Biotherapeutics
$30.00 /

-0.17 (-0.56%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

CMPI Checkmate Pharmaceuticals
$7.44 /

+0.3 (+4.20%)

BPTH Bio-Path
$6.21 /

-0.41 (-6.19%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

BGNE BeiGene
$300.84 /

+0.84 (+0.28%)

BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

AGEN Agenus
$2.70 /

-0.015 (-0.55%)

ADXS Advaxis
/

+

  • 17
    Mar
  • 10
    Mar
  • 16
    Feb
  • 09
    Feb
  • 04
    Feb
  • 05
    Feb
  • 20
    Jan
  • 13
    Jan
  • 08
    Jan
  • 07
    Jan
  • 18
    Dec
  • 16
    Dec
  • 02
    Dec
  • 24
    Nov
  • 22
    Oct
  • 09
    Oct
  • 25
    Sep
  • 25
    Sep
  • 07
    Aug
  • 30
    Jul
  • 24
    Jul
  • 09
    Jul
  • 01
    Jul
  • 17
    Jun
  • 09
    Jun
  • 29
    May
  • 29
    May
  • 22
    Apr
INCY Incyte
$82.13 /

+1.5 (+1.86%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

SURF Surface Oncology
$7.35 /

+0.095 (+1.31%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

RUBY Rubius Therapeutics
$23.77 /

+1.27 (+5.64%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

MRSN Mersana Therapeutics
$17.06 /

+0.89 (+5.50%)

JNCE Jounce Therapeutics
$9.74 /

+0.485 (+5.24%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

IMCR Immunocore
$39.50 /

+6.8 (+20.80%)

HARP Harpoon Therapeutics
$20.61 /

+0.73 (+3.67%)

GLSI Greenwich LifeSciences
$35.13 /

-0.92 (-2.55%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

ATNM Actinium Pharmaceuticals
$7.80 /

+0.23 (+3.04%)

ARVN Arvinas
$62.89 /

+1.62 (+2.64%)

ZNTL Zentalis
$47.04 /

+1.43 (+3.14%)

RVMD Revolution Medicines
$39.79 /

+2.18 (+5.80%)

REPL Replimune Group
$30.50 /

+0.32 (+1.06%)

PPBT Purple Biotech
$4.04 /

+ (+0.00%)

PMVP PMV Pharmaceuticals
$32.90 /

+0.06 (+0.18%)

INCY Incyte
$82.13 /

+1.5 (+1.86%)

CRSP Crispr Therapeutics
$123.29 /

+2.34 (+1.93%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

BDTX Black Diamond Therapeutics
$24.70 /

-0.7199 (-2.83%)

Wednesday
Hot Stocks
NV5 Global awarded $10M in infrastructure contracts in Florida and New York » 08:08
04/14/21
04/14
08:08
04/14/21
08:08
NVEE

NV5 Global

$94.69 /

-1.17 (-1.22%)

NV5 Global announced that…

NV5 Global announced that it has been awarded approximately $10M in infrastructure projects in Florida and New York. NV5 will provide engineering design, construction inspection, geotechnical engineering, and materials testing to support transportation, sewer, and water delivery improvements. The Florida Department of Transportation awarded NV5 a five-year contract to provide geotechnical engineering and materials testing services. The scope of the contract covers sections throughout the 260-mile span of the Florida Turnpike. Services will be provided by multiple NV5 offices throughout the state. In New York, NV5 was selected for a three-year contract to provide engineering design services to improve interstate access to the Hunts Point Peninsula in the Bronx, home to the largest food distribution facility in the United States. NV5's responsibilities include utility design for all sewer, water main, and private utilities, design of the multi-use path, and development of the required environmental permitting plans. NV5 was also awarded a one-year contract by the New York City Department of Design and Construction to provide resident engineering inspection services for sewer and water main work in Park Place between Underhill Avenue and Flatbush Avenue and other locations in Brooklyn.

ShowHide Related Items >><<
NVEE NV5 Global
$94.69 /

-1.17 (-1.22%)

NVEE NV5 Global
$94.69 /

-1.17 (-1.22%)

03/29/21 Roth Capital
Roth Capital positive on NV5 acquisition of Geodynamics
03/15/21 Baird
NV5 Global initiated with an Outperform at Baird
01/13/21 Roth Capital
NV5 Global price target raised to $136 from $82 at Roth Capital
11/12/20 Roth Capital
NV5 Global price target raised to $82 from $77 at Roth Capital
NVEE NV5 Global
$94.69 /

-1.17 (-1.22%)

  • 11
    Mar
NVEE NV5 Global
$94.69 /

-1.17 (-1.22%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.